May 24, 2024 07:15 AM EDTUpdated 08:02 AM R&DPharma AUTHORKatherine LewinNews [email protected] Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the company’s case for expanding the drug in a broad range of...
Month: <span>May 2024</span>
Post
Rates of severe multiple drug intolerance syndrome up in fibromyalgia, IBS
MAY 24, 2024 by Elana Gotkine Patients with fibromyalgia and irritable bowel syndrome (IBS) have increased rates of severe multiple drug intolerance syndrome (MDIS), according to a study published in the May issue of the Journal of Allergy and Clinical Immunology: In Practice. Alicia A. Alvarez, M.D., from Sarasota Memorial Hospital in Florida, and colleagues...
Post
Pharma firm urged to share new ‘game-changer’ HIV drug
MAY 30, 2024 Microscopic image of an HIV-infected T cell. Credit: NIAID More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly...
Post
Exercise and pain education no boost for chronic pain after knee replacement
MAY 30, 2024 by Lori Solomon Neuromuscular exercise and pain neuroscience education do not provide superior pain and function outcomes versus pain neuroscience education alone in patients with chronic pain after total knee arthroplasty (TKA), according to a study published online May 24 in JAMA Network Open. Jesper B. Larsen, Ph.D., from Aalborg University in...
Post
India left waiting another year for Wegovy
Novo Nordisk is ”very enagaged” in India, the CFO says, but the weight-loss drug will not be launched there until 2025. Photo: Tom Little BY CHRISTIAN BUNDGAARD28 May 2024at 09:50 People with obesity in India will have to wait to get access to Novo Nordisk’s big seller Wegovy, according to the local Indian media Business...
Post
Do You Really Know a UTI When You See It?
Medscape Medical News > Conference News > AUA 2024 Tara Haelle May 20, 2024 An updated clinical approach to diagnosing urinary tract infections (UTIs) that considers five potential phenotype categories instead of the usual three could aid clinical management and better center patient needs, according to the authors of a new study in The Journal...
Post
Cholesterol Denialism is Pseudoscience
theheart.org on MedscapeCOMMENTARY Christopher Labos, MD CM, MSc, FRCPC DISCLOSURES | May 02, 2024 How did cholesterol denialism become a pseudoscience? It happened so slowly that many of us didn’t notice. But somewhere along the way, cholesterol deniers stopped questioning the scientific evidence and started denying it. Christopher Labos, MD CM, MSc If you weren’t...
Post
Test-at-home kit for cancer patients approved for use
10 May 2024 By Shiona McCallum,Technology reporter A new device to help reduce the time cancer patients spend in hospital has been given regulatory approval. The Liberty allows patients to take blood tests – and upload the results – at home, and without supervision. Its users say it allows them to cut down on draining...
Post
FDA panel gives nod to blood test for colon cancer
MAY 26, 2024 by Robin Foster A U.S. Food and Drug Administration advisory panel on Thursday recommended the approval of a new blood test that can spot colon cancer. The panel voted 7-2 that the benefits outweighed the risks when using the Guardant Health’s Shield test for colon cancer. “The advisory committee’s strong support for...
Post
GI Complications With GLP-1s for Weight Loss: Reexamining the Risks
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 23, 2024 WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 (GLP-1) receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction, a new retrospective study found no significant link to these complications. The...